Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 1

Interventions

Cytarabine 34Cyclophosphamide 21Vincristine 20Methotrexate 18Dexamethasone 18Mercaptopurine 16Idarubicin 16nilotinib 15Daunorubicin 15Imatinib Mesylate 13fludarabine 12Granulocyte Colony-Stimulating Factor 12Asparaginase 12Rituximab 11Doxorubicin 10Prednisolone 9Etoposide 8Prednisone 7Thioguanine 6Teniposide 6Mitoxantrone 6Dasatinib 6venetoclax 5fludarabine phosphate 5Vindesine 5Stem Cell Transplantation 5Ifosfamide 5Azacitidine 4posaconazole 3pirtobrutinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Immunosuppressive Agents × Other hematologic neoplasm × Clear all
NCT03150134 2017-05-12

Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 4 Unknown
100 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡